MaxCyte, Inc. (MXCT) has a MoatMap StockRank of 23/100 based on Quality (40/100), Value (45/100), and Momentum (26/100) factor scores. The current signal is SELL. MaxCyte provides cell engineering platform technologies (electroporation) to biotech and pharma. While it has a high-margin licensing model, it is currently unprofitable and faces a slowdown in biotech R&D spending, failing our strict quality and momentum screens.
MaxCyte, Inc. is a leading provider of cell-engineering platform technologies, specializing in high-performance electroporation systems for cell-based therapies and drug discovery. The company's proprietary Flow Electroporation technology is utilized by major biopharmaceutical companies to engineer cells with high efficiency and viability. MaxCyte's competitive moat is secured by its extensive portfolio of commercial licenses, which generate recurring instrument, disposable, and milestone-based royalty revenues.
| Price | $1.19 |
| Market Cap | $125M |
| P/E (Forward) | -4.94 |
| Price/Book | 0.78 |
| Return on Equity | -21.3% |
| Return on Invested Capital | -24.1% |
| Debt/Equity | 10.42 |
| Gross Margin | 80.5% |
| Operating Margin | -64.1% |
| Revenue Growth | -7.1% |
| Free Cash Flow | $-14M |
MaxCyte, Inc. operates in the Medical Devices industry, part of the Healthcare sector (United States).